Navigation Links
Hard To Treat Diseases (HTDS) To Disperse Special One Time Hiru (HIRU) Common Stock
Date:1/12/2010

SHENZHEN, China, Jan. 12 /PRNewswire-FirstCall/ - Hard to Treat Diseases, Inc. (HTDS; www.htdsmedical.com) announced that its directors have resolved that up to 40,000,000 shares of Hiru Corporation (HIRU.PK) HTDS received for the sale of its MindUp division to Hiru will be distributed to HTDS shareholder as a special onetime payment of kind.

Terry Yuan, HTDS President, said, "In our efforts to maximize shareholder value, we believe that the distribution of the Hiru shares will benefit our shareholders." The Hiru stock will be distributed to shareholders of record on a date to be set by the company in consultation with FINRA. The Hiru shares will be restricted and not immediately freely tradable. HTDS shareholders holding HTDS on the record date will not be required to take any action to receive the Hiru common shares on the distribution date. Consummation of the special onetime distribution is subject to the approval of FINRA.

In other company news and events, the company continues to work with Pink Sheets who is not a registered SRO to have the toon type skull and bones icon removed from HTDS quote. (SRO see http://en.wikipedia.org/wiki/Self-regulatory_organization) The company management feels that Pink Sheets should remain neutral and not punish any company with the "traffic signals" once the company has identified a naked short seller publicly or when the company issues a forward guidance report to its shareholders. Now, it appears that finally FINRA is taking notice of Pink Sheets actions on many levels http://www.sec.gov/rules/sro/finra/2009/34-60999.pdf. The company disagrees with many assertions made by Pink Sheets as self serving http://brokeandbroker.com/images/PinkSheetProp.pdf

The company will shortly order a NOBO list and a DTC Run from its transfer agent to establish where and how some market makers continue to offer HTDS stock for sale and what instruments are being used to hedge these sales. The company repeats again that its security is grossly undervalued and places a valuation on its share price in the several penny price range. The company vows to do all it can to see these values returned to its shareholder base.

All of this comes on a heel of the company signing major contracts Internationally, a 1 time special distribution and some previously announced pending contracts, including possible merger discussion with a USA based nutrient replenishing company in a Health Care, Surgical Wound Healing Trauma Victims Diabetics sector.

To receive future updates, via email including quarterly newsletters and company updates which may not be newsworthy however important to the reader and followers of the company please sign up today free at www.minamargroup.com/updates.

Safe Harbor Statement

Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

CONTACT: For medical and scientific dialogue inquiry only, please contact medicalinfo@htdsmedical.com; For any corporate matters, please contact www.minamargroup.com/helpdesk

SOURCE Hard to Treat Diseases


'/>"/>
SOURCE Hard to Treat Diseases
Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. Using coxibs and NSAIDs to treat osteoarthritis
2. New treatment effective in counteracting cocaine-induced symptoms
3. New treatment boosts muscle function in myasthenia gravis
4. HPV vaccine does not appear to be effective for treating pre-existing HPV infection
5. Free distribution of insecticide-treated mosquito nets can save lives
6. Kenyan malaria success strengthens call for free insecticide-treated nets for all
7. Broad-based group of physicians calls for improvement in stroke treatment
8. Cranberry Could Juice Up Ovarian Cancer Treatment
9. Is 4 agents decoction (Si Wu Tang) efficacious in treating primary dysmenorrhea?
10. Non-medicinal treatment touted for pre-schoolers with ADHD
11. Nonmedicinal treatment touted for preschoolers with ADHD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... ... in a crisis. Her son James, eight, was out of control. Prone to extreme mood ... something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a ... children and say he was going to kill them. If we were driving on ...
(Date:6/24/2016)... San Francisco, CA (PRWEB) , ... June 24, ... ... at CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has ... , self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... People across ... in Genome magazine’s Code Talker Award, an essay contest in which patients and their ... award to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Investment Group (TGIG), has initiated cultivation and processing operations at its production facility, ... Pahrump, Nevada. , Puradigm is the manufacturer of a complete system of proactive ...
(Date:6/24/2016)... ... June 24, 2016 , ... Venture Construction Group (VCG) sponsors ... on June 20th at the Woodmont Country Club at 1201 Rockville Pike, Rockville, Maryland, ... to helping service members that have been wounded in battle and their families. Venture ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
(Date:6/23/2016)... , June 23, 2016 Research and ... News Issue 52" report to their offering. ... influenza treatment creates a favourable commercial environment for MedImmune to ... patient base that will serve to drive considerable growth for ... would serve to cap sales considerably, but development is still ...
(Date:6/23/2016)... , June 23, 2016 ... Oticon , industry leaders in advanced ... launch of Oticon Opn ™, the world,s first ... of possibilities for IoT devices.      (Photo: ... Oticon introduces a number of ,world firsts,: ...
Breaking Medicine Technology: